UCB SA (OTCMKTS:UCBJF) Sees Significant Decline in Short Interest

UCB SA (OTCMKTS:UCBJF) was the recipient of a significant drop in short interest in the month of October. As of October 31st, there was short interest totalling 403,500 shares, a drop of 17.0% from the October 15th total of 486,100 shares. Based on an average daily volume of 100 shares, the short-interest ratio is presently 4,035.0 days.

UCB Price Performance

Shares of UCBJF opened at $194.76 on Friday. The firm has a 50 day simple moving average of $181.53 and a 200-day simple moving average of $157.20. UCB has a 1-year low of $69.70 and a 1-year high of $194.76. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.